The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 04, 2017

Filed:

Aug. 10, 2012
Applicants:

Dean Burkin, Sparks, NV (US);

Ryan Wuebbles, Sparks, NV (US);

Pam Van Ry, Reno, NV (US);

Inventors:

Dean Burkin, Sparks, NV (US);

Ryan Wuebbles, Sparks, NV (US);

Pam Van Ry, Reno, NV (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 38/17 (2006.01); C12Q 1/68 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1709 (2013.01); A61K 38/1732 (2013.01); C12Q 1/6883 (2013.01); G01N 33/6896 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/42 (2013.01); G01N 2333/4724 (2013.01); G01N 2500/00 (2013.01); G01N 2800/2878 (2013.01); G01N 2800/2885 (2013.01); G01N 2800/52 (2013.01);
Abstract

Disclosed herein are methods for diagnosing, prognosing and treating muscular dystrophy. The disclosed methods can be used to diagnosis, prognosis or treat a subject with merosin-deficient congenital muscular dystrophy Type 1A (MDC1A), limb-girdle muscular dystrophy (LGMD), facioscapulohumeral (FHMD), Beckers muscular dystrophy (BMD) or Duchenne muscular dystrophy (DMD). Also disclosed are methods of determining the effectiveness of an agent for the treatment of muscular dystrophy. In an example, a method of diagnosing or prognosing a subject with muscular dystrophy includes detecting expression of Galectin-1 or Galectin-3 in a sample obtained from the subject at risk of having or having one or more signs or symptoms associated with muscular dystrophy, thereby diagnosing or prognosing the subject with muscular dystrophy. Also provided are methods of enhancing muscle regeneration, repair, or maintenance in a subject by administering galectin, such as Galectin-1 and/or Galectin-3 to a subject in need thereof.


Find Patent Forward Citations

Loading…